LUNALI
CMC SOLUTIONS
Small Molecule CMC Strategy & Execution
LUNALI provides integrated CMC leadership for small-molecule therapeutics from conventional compounds to complex modalities such as PROTACs, with capabilities extending to selected short synthetic peptides. We assemble experienced specialists to develop phase-appropriate strategies, solve technical challenges, and advance programs efficiently from early development through commercialization.
Why LUNALI
Execution Aligned with Your Strategy
We do more than provide recommendations. LUNALI works alongside your team and external partners to translate CMC strategy into concrete deliverables, resolve problems as they arise, and keep your development program moving forward.
Cost-Efficiency By Experience
Emerging companies must make every dollar and every week count. Our competitive rates and senior experience enable efficient, phase appropriate strategies focused on the next value creating milestone not overbuilding for a hypothetical future. We clearly define downstream risks and help you decide what must be addressed now and what can responsibly wait.
The Right Expertise, Carefully Chosen
Every LUNALI team is personally assembled by founder Johann Chan around the client’s specific needs and ways of working. Specialists are selected not only for deep technical expertise, sound judgment, and reliability, but also for their character, communication style, and ability to work collaboratively as a committed member of the client’s team.
Expert CMC Leadership
LUNALI CMC Solutions LLC is a senior-level biopharma consulting firm founded by Johann Chan, PhD. We specialize in advancing synthetic drug candidates through expert CMC strategy and technical support, lowering the barriers to high-quality support for biotech and pharmaceutical executives.
